Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

2.

Checkpoint Immunotherapy: Picking a Winner.

Teng MW, Khanna R, Smyth MJ.

Cancer Discov. 2016 Aug;6(8):818-20. doi: 10.1158/2159-8290.CD-16-0694.

3.

Hallmarks of response to immune checkpoint blockade.

Cogdill AP, Andrews MC, Wargo JA.

Br J Cancer. 2017 Jun 27;117(1):1-7. doi: 10.1038/bjc.2017.136. Epub 2017 May 18. Review.

4.
5.

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.

J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.

6.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

7.

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

Rojas JJ, Sampath P, Hou W, Thorne SH.

Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.

8.

Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Huffaker TB, Lee SH, Tang WW, Wallace JA, Alexander M, Runtsch MC, Larsen DK, Thompson J, Ramstead AG, Voth WP, Hu R, Round JL, Williams MA, O'Connell RM.

J Biol Chem. 2017 Nov 10;292(45):18530-18541. doi: 10.1074/jbc.M117.808121. Epub 2017 Sep 14.

9.

Immune Checkpoint Therapy in Melanoma.

Callahan MK.

Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183. Review.

PMID:
27111901
10.
11.

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].

Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F.

Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26. Review. French.

PMID:
28131419
12.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

13.

Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.

Hu ZI, Ho AY, McArthur HL.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26. Review.

PMID:
28816141
14.

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.

Lechner A, Schlößer H, Rothschild SI, Thelen M, Reuter S, Zentis P, Shimabukuro-Vornhagen A, Theurich S, Wennhold K, Garcia-Marquez M, Tharun L, Quaas A, Schauss A, Isensee J, Hucho T, Huebbers C, von Bergwelt-Baildon M, Beutner D.

Oncotarget. 2017 Jul 4;8(27):44418-44433. doi: 10.18632/oncotarget.17901.

15.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS.

Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.

16.

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA.

Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.

17.

Immune Checkpoint Blockade in Cancer Therapy.

Postow MA, Callahan MK, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. Review.

18.

Immune Checkpoint Inhibitors in Organ Transplant Patients.

Kittai AS, Oldham H, Cetnar J, Taylor M.

J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180. Review.

PMID:
28719552
19.

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Allard B, Pommey S, Smyth MJ, Stagg J.

Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. Epub 2013 Aug 27.

20.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

Supplemental Content

Support Center